Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Background We previously reported elsewhere of a follicular lymphoma patient suffering
from persistent COVID-19 pneumonia that was still ongoing at 2 months after onset …

Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a
severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 …

Convalescent plasma (CP) therapy might be effective in patients with haematological
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …

Background Patients with haematological malignancies have an increased susceptibility for
COVID-19 and higher mortality. They may also have prolonged symptoms and viral …

Background: Immunocompromised patients, including those with hematological
malignancies, are at a high risk of developing severe coronavirus disease 2019 (COVID-19) …

During the ongoing COVID-19 epidemic many efforts have gone into the investigation of the
SARS-CoV-2–specific antibodies as possible therapeutics. Currently, conclusions cannot be …

We report on a case of severe COVID-19 in a 50-year-old male patient who was treated with
an infusion of parenteral mesenchymal stem cells (MSC)(Table 1). The pathophysiologic …

During the pre-vaccine era of the COVID-19 pandemic convalescent plasma has once again
emerged as a major potential therapeutic form of passive immunization that in specific cases …

Since the first case of coronavirus disease 2019 (COVID-19) in November 2019, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has undergone continuous …